
|Articles|July 18, 2019
Management of ocular inflammation and pain using novel insert
Author(s)Julianne Mobilian
ICMYI: Dr. Tyson shares his pearls using the dexamethasone 0.4 mg insert (Dextenza, Ocular Therapeutix).
Advertisement
Sydney Tyson, MD, shares the take-home message from the presentation he delivered at the 2019
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
Nanoscope secures new US patent for Multi-Characteristic Opsin (MCO) technology platform
2
Glaucoma innovation: Eight themes to watch in 2026
3
Ollin Biosciences reports positive head-to-head phase 1b data for OLN324 vs faricimab
4
First patient treated in dose-expansion portion of SpliceBio's phase 1/2 ASTRA clinical trial
5












































